- Home
- ASRT
as 02-21-2025 4:00pm EST
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | LAKE FOREST |
| Market Cap: | 78.3M | IPO Year: | 1997 |
| Target Price: | $3.19 | AVG Volume (30 days): | 320.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $1.80 | Next Earning Date: | 03-10-2025 |
| Revenue: | $125,763,000 | Revenue Growth: | -25.77% |
| Revenue Growth (this year): | -18.54% | Revenue Growth (next year): | 1.84% |
Latest Assertio Holdings Inc. News
ASRT Breaking Stock News: Dive into ASRT Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
Investors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 87% over the last five years
GlobeNewswire
2 months ago
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
GlobeNewswire
2 months ago
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
GlobeNewswire
2 months ago
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO
GlobeNewswire
3 months ago
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
Simply Wall St.
3 months ago
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
3 months ago
Q3 2024 Assertio Holdings Inc Earnings Call
Compare ASRT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASRT Assertio Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.